REVIVE(Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient)

Inclusion criteria

• Histologically or clinically diagnosed as alcoholic liver cirrhosis
• Classified as Child-Pugh grade B or C
• Age of 20 ~ 70 years
• Capable of conducting hepatic artery catheterization which inserts a catheter up to the hepatic artery
• In the case of fertile women, confirmed as negative in pregnancy test when screening, and agreed to avoid pregnancy during the trial period
• Women capable of pregnancy must satisfy the following conditions; Has been through menopause for at least 1 year, has no possibility of pregnancy via surgery/procedure, or effectively used acceptable contraceptive methods (Intrauterine device-loop, mirena, diaphragm or condom/femidom, oral contraceptive pills, non-oral contraceptives)
• Patient who can agree to participate in the clinical trial by oneself or by one's legal representative
• Able to conduct the clinical trial according to the protocol

Exclusion criteria

• Diagnosed with malignant hematologic disease (acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) and not cured from it
• Patient with severe aplastic anemia
• Has a medical record of solid cancer(within 5 years prior to screening), or diagnosed with solid cancer and currently receiving cancer treatment
• Incapable of conducting hepatic artery
• Patient who consumed alcohol and took hepatotoxic drugs within 6 months prior to registration
• Has continuously taken a large amount of steroids or antibiotics for 1 month prior to registration
• Judged by a researcher to have had major orthopedic surgery, organ biopsy, or similar external injury within 3 months prior to registration
• Evidence of active autoimmune liver disease
• Patient with extrahepatic biliary stricture
• Patient who conducted transjugular intrahepatic portosystemic shunt
• Has active thrombosis of the portal or hepatic veins
• Patient with sepsis
• Patient who suffers heart, renal, respiratory failure
• Patient who is positive in pathogenic test (HIV, Syphilis,HBV,HCV)
• Pregnant or lactating woman
• Patient who cannot adapt to the protocol and follow-up observation
• Patient who has experienced drug abuse for the past 1 year
• Participated in the other clinical trials within 30 days before registration
• Patient with any disease or condition which the investigator feel would interfere with trial or the safety of the subject